within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BX17_SodiumSalicylateAndMethe;

model SodiumSalicylateAndMethe
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 6.944444444444445e-07,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.0002,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>SodiumSalicylateAndMethenamine</td></tr><tr><td>ATC code:</td><td>G04BX17</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Sodium salicylate and methenamine is a combination drug formerly used for the treatment of urinary tract infections (UTIs). Methenamine acts as a urinary antiseptic by releasing formaldehyde in acidic urine, while sodium salicylate was used for its analgesic and anti-inflammatory effects. This combination is largely obsolete and is not commonly used or approved for UTI treatment today due to more effective and safer alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for an adult oral dose in absence of direct published PK models for the combination product.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G04BX17 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end SodiumSalicylateAndMethe;
